Angiogenesis 2023: Efficacy and safety of high-dose aflibercept for treatment of DMEFebruary 28th 2023
David S. Boyer, MD, presented data from the PHOTON study examining the safety and efficacy of high-dose aflibercept for treatment of diabetic macular edema at the 2023 Angiogenesis, Exudation, and Degeneration conference.
Angiogenesis 2023: Ocular Therapeutix announces data from phase 1 clinical trial evaluating OTX-TKI for treatment of Wet AMDFebruary 12th 2023
The company noted that all OTX-TKI treated subjects who were rescue-free at the Month 7 interim analysis remained rescue-free, extending the 73% rescue-free rate up to Month 10.
Ellipsoid zone integrity in dry AMD focus of presentation at Angiogenesis 2023February 10th 2023
In a presentation at the Angiogenesis, Exudation, and Degeneration 2023 conference, Justis Ehlers, MD, presented "Ellipsoid Zone Integrity in Dry AMD: An Imaging Biomarker for Progression Risk and Clinical Trial Endpoint.”
Angiogenesis 2023: Reversing the tides of AMD with drug targeting mitochondria to improve photopic visionFebruary 10th 2023
In a presentation at the Angiogenesis, Exudation, and Degeneration 2023 meeting hosted by Bascom Palmer Eye Institute, Baruch Kupperman, MD, PhD, detailed research in which investigators evaluated risuteganib for safety and effectiveness in patients with dry AMD.
Angiogenesis 2023: Visual functional loss in geographic atrophyFebruary 10th 2023
In a presentation at the 2023 Angiogenesis, Exudation, and Degeneration program, Usha Chakravarthy, PhD, FRCOphth, CBE, presented data from the trial of lampalizumab, which is peeling back some of the mystery shrouding geographic atrophy.
Angiogenesis 2023: Ophthalmic artery angioplasty to treat age-related macular degenerationFebruary 10th 2023
In a presentation at Bascom Palmer’s 2023 Angiogenesis, Exudation, and Degeneration conference in Miami, Pedro Lylyk, MD, said ophthalmic artery angioplasty could prove to be a treatment option for patients diagnosed with age-related macular degeneration.
Angiogenesis 2023: GA phenotypes and progression rates in Asians vs non-AsiansFebruary 10th 2023
A study conducted by Gemmy Cheung, MBBS, FRCOphth and colleagues shows geographic atrophy (GA) lesion phenotypes, associated features, and growth rates differ between Asians and non-Asians.
CANDELA study: Phase 2 results for high dose aflibercept 8 mg for wet AMDFebruary 17th 2022
At Angiogenesis, Dr. David Brown presented the Phase 2 results of the CANDELA study for high dose aflibercept 8 milligram for wet AMD; here, he discusses those results.
Unity provides Phase 1 study data for UBX1325February 14th 2022
During a presentation at the Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 conference, Robert Bhisitkul, MD, PhD, provided 24-week clinical data from the Phase 1 study, demonstrating that patients with DME and wAMD showed improved visual acuity through 24 weeks following a single dose of UBX1325.
Stargardt research: Therapy on the horizon for inherited retinal diseaseFebruary 12th 2022
Dr. Carel Hoyng divulges the main takeaways from his Angiogenesis presentation, including the origins of Stargardt disease, correct diagnosis, ongoing gene therapy trials and the future of therapy.
KALAHARI Study shows THR-149 is safe, well-tolerated for DMEFebruary 12th 2022
Arshad M. Khanani, MD, MA, told attendees at the Bascom Palmer Eye Institute’s 19th annual Angiogenesis, Exudation, and Degeneration 2022 Virtual Edition that data from the part A of the KALAHARI trial is encouraging, showing that THR-149 has the potential to improve vision in patients with DME who have a sub-optimal response to anti-VEGF therapies.
Deep learning analysis detects diabetic retinopathy on ultra-widefield scanning laser ophthalmoscope imagesFebruary 12th 2022
During her talk at Angiogenesis, Dr. Loewenstein outlines how artificial intelligence could revolutionize diabetic retinopathy screening.
DAVIO trial finds positive safety results for EYP-1901 for wet AMDFebruary 12th 2022
Jay S. Duker, MD, who presented data at the Bascom Palmer Eye Institute’s 19th annual Angiogenesis, Exudation, and Degeneration 2022 Virtual Edition, noted that previously treated patients showed a significantly reduced treatment
Xiflam inhibits initiation of the inflammatory cascadeFebruary 11th 2022
During a presentation at the Bascom Palmer Eye Institute's Angiogenesis, Exudation, and Degeneration 2022 Virtual Edition conference, David S. Boyer, MD, explained that the drug, which is being considered to treat diabetic retinopathy, renal disease, and age-related macular degeneration, is intended to be an alternative therapy to monthly chronically administered intravitreal injections of anti-VEGF drugs.
Post hoc analysis of patients in avacincaptad pegol clinical trial shows growth of GA lesions slowedFebruary 11th 2022
In a presentation at the Bascom Palmer Eye Institute’s 19th annual Angiogenesis, Exudation, and Degeneration 2022 Virtual Edition, Glenn J. Jaffe, MD, noted that the analysis showed, for the first time, a decreased growth rate in the central foveal area by a therapeutic intervention when compared with sham treatment.
Study finds subretinal implant for advanced dry AMD is safe, well-toleratedFebruary 11th 2022
In a presentation at the Bascom Palmer Eye Institute’s 19th annual Angiogenesis, Exudation, and Degeneration 2022 Virtual Edition, Amir Kashani, MD, PhD, discussed results that show the implant procedure is feasible on an outpatient basis and has a good safety and efficacy profile.
Blocking Connexin-43 may improve diabetic retinopathy, AMDFebruary 11th 2022
Dr. David S. Boyer describes how blocking Connexin-43 may improve the retinal vascular system function in patients with diabetes, potentially creating a future of oral medication for treatment of diabetic retinopathy and AMD.
Angiogenesis 2022: Retina specialists are excited for these 10 scientific sessionsJanuary 25th 2022
This Bascom Palmer Eye Institute 2-day virtual scientific program promises a distinguished international faculty who will share the latest developments in imaging, translational research, and clinical trials as well as the impact these advances will have on clinical ophthalmology.